ABSTRACT
Objective:To study the clinical effect and safety of aerosol inhalation of recombinant human interferon α-2b( P. puti-da) in the children with viral upper respiratory tract infection ( VURI) . Methods: Totally 100 children diagnosed as viral upper re-spiratory tract infection were randomly divided into the observation group and the control group with 50 cases in each. The two groups of children were both given symptomatic and supportive treatment, and the observation group was given IFN-α2b (P. putida) 150 000 IU·kg-1 ·d-1 in 2-4 ml 0. 9% sodium chloride injection with aerosol inhalation, qd, 5-10 min each time, and the control group was given ribavirin 10-15 mg·kg-1 ·d-1 in 5% glucose injection 150 ml, ivd, and a course of treatment was continuous 5 d. The fever, cold symptoms ( catarrh, cough, malaise) and clinical efficiency of the two groups were compared. Results:The defervescence effect of the observation group was significantly higher than that of the control group after the treatment(P<0. 05). The effect in the children with mild and moderate cough in the observation group was better than that in the control group, and the changes were statistically sig-nificant difference(P<0. 01). The heat range, cough fading time, catarrh symptom and systemic symptom disappearance time in the observation group were significantly better than those in the control group(P<0. 05). The clinical efficient rate of the observation group was 96. 0%, which was significantly higher than that (84. 0%) in the control group(P<0. 05) . Conclusion: Combined with the conventional therapy, aerosol inhalation of IFN-α2b can be effectively and safely used for treating viral upper respiratory tract infec-tion in children, which is worthy of popularized use in clinics.
ABSTRACT
Aim To observe the effect of recombinant human interferon and verazole used alone or in combination in resisting respiratory synthesis virus (RSV) in vitro. Methods RSV strains were proliferated with Hela cells in Eagles solution on a 96 hole plate. The recombinant human interferon and virazole were diluted to different concentrations and were separately added in the dose of 100 ?l to each hole of the plate. After 48 hours cultured, the concentrations of the drugs for inhibiting cytopathogenic effect(CPE)of RSV were determined. Results When the concentration of interferon was ≥5 U?ml -1 and virazlole ≥24 ?g?ml -1 ,respectively,the effect of the two drugs on inhibiting the CPE of RSV was remarkable and was improved with their concentration increasing .When the concentrations of the two drugs were lower than that of their effect respectively , their united use also had obvious effect in resisting the virus. In addition, the different using methods of interferon have also different results. Conclusion Both recombinant human interferon and virazole are effective in inhibiting RSV in vitro and will bring about better effect when used in combination.